[{"id":"3bafa6d0-29f9-4e0c-8308-7ec0cbbe6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03010358","created_at":"2021-01-18T14:49:09.492Z","updated_at":"2024-07-02T16:35:40.703Z","phase":"Phase 1/2","brief_title":"Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03010358","lead_sponsor":"Alexey Danilov, MD","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • entospletinib (GS-9973)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 04/29/2021","primary_completion_date":" 04/29/2021","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-08-08"}]